[
  {
    "ts": null,
    "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2025 Update",
    "summary": "GMOâs 13F portfolio grew to $33.23B in Q2 2025, with Microsoft, Meta, Alphabet, Oracle, and Apple as top holdings. Read more about the portfolio here.",
    "url": "https://finnhub.io/api/news?id=1752da494c03f4d1c83d55ee99d4a662014fa49c4d61c67a181e3e504c898d52",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755726539,
      "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2025 Update",
      "id": 136449150,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "ELV",
      "source": "SeekingAlpha",
      "summary": "GMOâs 13F portfolio grew to $33.23B in Q2 2025, with Microsoft, Meta, Alphabet, Oracle, and Apple as top holdings. Read more about the portfolio here.",
      "url": "https://finnhub.io/api/news?id=1752da494c03f4d1c83d55ee99d4a662014fa49c4d61c67a181e3e504c898d52"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth's Push Into Home Health: A New Growth Chapter?",
    "summary": "UNH is expanding further into home health with Optum, fueled by a $3.3B Amedisys deal to boost value-based care growth.",
    "url": "https://finnhub.io/api/news?id=bbddcbd6944d5a02f27c6ef318fc3dafcaa0e1332b2c27fefd824f824ba5bf1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755709260,
      "headline": "UnitedHealth's Push Into Home Health: A New Growth Chapter?",
      "id": 136450353,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "UNH is expanding further into home health with Optum, fueled by a $3.3B Amedisys deal to boost value-based care growth.",
      "url": "https://finnhub.io/api/news?id=bbddcbd6944d5a02f27c6ef318fc3dafcaa0e1332b2c27fefd824f824ba5bf1e"
    }
  },
  {
    "ts": null,
    "headline": "Elevance loses Medicare Advantage star ratings suit",
    "summary": "The Texas judge’s decision — which picked apart Elevance’s argument on mathematical grounds — is expected to cost Elevance $375 million, though the insurer could still appeal.",
    "url": "https://finnhub.io/api/news?id=2595626b8a32804290bd321f6d5cb54423a8868dede57f13fbef19ae2f679b5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755683090,
      "headline": "Elevance loses Medicare Advantage star ratings suit",
      "id": 136437805,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "The Texas judge’s decision — which picked apart Elevance’s argument on mathematical grounds — is expected to cost Elevance $375 million, though the insurer could still appeal.",
      "url": "https://finnhub.io/api/news?id=2595626b8a32804290bd321f6d5cb54423a8868dede57f13fbef19ae2f679b5a"
    }
  },
  {
    "ts": null,
    "headline": "Winners And Losers Of Q2: Elevance Health (NYSE:ELV) Vs The Rest Of The Health Insurance Providers Stocks",
    "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Elevance Health (NYSE:ELV) and its peers.",
    "url": "https://finnhub.io/api/news?id=fa331db934e019a4e4064bf2222736dbec06f6820d42d9839a05e683918f960c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755660799,
      "headline": "Winners And Losers Of Q2: Elevance Health (NYSE:ELV) Vs The Rest Of The Health Insurance Providers Stocks",
      "id": 136437806,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Elevance Health (NYSE:ELV) and its peers.",
      "url": "https://finnhub.io/api/news?id=fa331db934e019a4e4064bf2222736dbec06f6820d42d9839a05e683918f960c"
    }
  }
]